Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Revenue (2017 - 2025)

Crinetics Pharmaceuticals has reported Revenue over the past 9 years, most recently at $6.2 million for Q4 2025.

  • Quarterly results put Revenue at $6.2 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $7.7 million (up 640.71% YoY), and the annual figure for FY2025 was $7.7 million, up 640.71%.
  • Revenue for Q4 2025 was $6.2 million at Crinetics Pharmaceuticals, up from $143000.0 in the prior quarter.
  • Over the last five years, Revenue for CRNX hit a ceiling of $6.2 million in Q4 2025 and a floor of $143000.0 in Q3 2025.
  • Median Revenue over the past 5 years was $674500.0 (2022), compared with a mean of $1.3 million.
  • Biggest five-year swings in Revenue: tumbled 76.11% in 2024 and later surged 158.4% in 2025.
  • Crinetics Pharmaceuticals' Revenue stood at $1.1 million in 2021, then tumbled by 34.23% to $709000.0 in 2022, then crashed by 51.2% to $346000.0 in 2023, then increased by 15.32% to $399000.0 in 2024, then skyrocketed by 1444.11% to $6.2 million in 2025.
  • The last three reported values for Revenue were $6.2 million (Q4 2025), $143000.0 (Q3 2025), and $1.0 million (Q2 2025) per Business Quant data.